He Siyu, Wu Li, Li Xue, Sun Hongyu, Xiong Ting, Liu Jie, Huang Chengxi, Xu Huipeng, Sun Huimin, Chen Weidong, Gref Ruxandra, Zhang Jiwen
Center for Drug Delivery Systems, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharm Sin B. 2021 Aug;11(8):2362-2395. doi: 10.1016/j.apsb.2021.03.019. Epub 2021 Mar 13.
Metal-organic frameworks (MOFs), comprised of organic ligands and metal ions/metal clusters coordinative bonds are highly porous, crystalline materials. Their tunable porosity, chemical composition, size and shape, and easy surface functionalization make this large family more and more popular for drug delivery. There is a growing interest over the last decades in the design of engineered MOFs with controlled sizes for a variety of biomedical applications. This article presents an overall review and perspectives of MOFs-based drug delivery systems (DDSs), starting with the MOFs classification adapted for DDSs based on the types of constituting metals and ligands. Then, the synthesis and characterization of MOFs for DDSs are developed, followed by the drug loading strategies, applications, biopharmaceutics and quality control. Importantly, a variety of representative applications of MOFs are detailed from a point of view of applications in pharmaceutics, diseases therapy and advanced DDSs. In particular, the biopharmaceutics and quality control of MOFs-based DDSs are summarized with critical issues to be addressed. Finally, challenges in MOFs development for DDSs are discussed, such as biostability, biosafety, biopharmaceutics and nomenclature.
金属有机框架材料（MOFs）由有机配体和金属离子/金属簇通过配位键构成，是具有高度多孔性的晶体材料。其可调的孔隙率、化学成分、尺寸和形状以及易于进行表面功能化，使得这个大家族在药物递送方面越来越受欢迎。在过去几十年里，人们对设计具有可控尺寸的工程化MOFs用于各种生物医学应用的兴趣与日俱增。本文对基于MOFs的药物递送系统（DDSs）进行了全面综述并展望未来，首先根据构成金属和配体的类型对适用于DDSs的MOFs进行分类。然后，阐述了用于DDSs的MOFs的合成与表征，接着介绍了药物负载策略、应用、生物药剂学和质量控制。重要的是，从药物制剂、疾病治疗和先进DDSs的应用角度详细介绍了MOFs的各种代表性应用。特别总结了基于MOFs的DDSs的生物药剂学和质量控制以及需要解决的关键问题。最后，讨论了用于DDSs的MOFs开发中面临的挑战，如生物稳定性、生物安全性、生物药剂学和命名法。
